Curve Therapeutics Celebrates Investment

Southampton Science Park based biotech company, Curve Therapeutics has raised over £40.5 million in Series A financing. This significant investment will help Curve to rapidly advance its Microcycle powerful drug discovery platform. Pfizer Ventures led the funding round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.

The company’s CEO, Dr Simon Kerry, said: "This financing will enable us to expand our team, progress our lead assets into the clinic and to expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth."

Professor Ali Tavassoli, CSO, added: "Curve's Microcycle platform is a powerful tool for drug discovery, enabling an unparalleled advantage in the discovery of functional hits and leads. We look forward to maximising the potential of our platform to further develop a rich pipeline of programmes with the potential to treat unmet clinical needs in a diverse range of diseases, including cancer."

Dr Marie-Claire Peakman, Partner at Pfizer Ventures, commented: "We are delighted to have led this financing and to work with great co-investors and leadership team.  Curve's platform provides an exciting new approach designed to tackle tough, high-priority targets which have been difficult to progress in the past. We are eager for the Company to progress the platform with the goal of identifying new therapeutics for challenging diseases."

Curve Therapeutics occupies state-of-the-art laboratories at the Southampton Science Park which has facilitated an expansion of its research team.

With four Universities and pioneering medical institutions including the Centre for Cancer Immunology in Southampton, Hampshire is an attractive location for life science companies.